This Article  • References  • Full text PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (119)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Clinical Analysis of 445 Patients and Suggestions for a Modification of Existing Classifications

Klaus Zerres, MD; Sabine Rudnik-Schöneborn, MD

Arch Neurol. 1995;52(5):518-523.

Abstract
Objectives
To describe the natural history in all types of proximal spinal muscular atrophy (SMA) and to propose a modified classification scheme that takes the longterm course of SMA into account.

Design
Patients with proximal SMA were studied prospectively and retrospectively in a genetic study that was based on clinical and family data.

Patients
Four hundred forty-five patients with SMA were ascertained since 1985 through various departments of neurology and neuropediatrics, institutes of human genetics, and the German muscular dystrophy association (Deutsche Gesellschaft für Muskelkranke, Freiburg, Germany).

Results
The study group was subdivided into patients with four types of SMA (ie, SMA types I, II, III, and IV) on the basis of achieved motor development and age at onset. Survival probabilities at 2, 4, 10, and 20 years of age were 32%, 18%, 8%, and 0%, respectively, in patients with SMA type I (those who were never able to sit) and 100%, 100%, 98%, and 77%, respectively, in patients with SMA type II (those who were able to sit but were unable to walk). Nineteen of 104 patients with SMA type II lost the ability to sit; this inability to sit was not of prognostic relevance. Patients with SMA type III (those who were able to walk [age at onset, younger than 30 years]) were subdivided into those with an age at onset before (SMA type IIIa) and after (SMA type IIIb) 3 years. The probabilities of being ambulatory at 10, 20, and 40 years after onset were 73%, 44%, and 34%, respectively, in patients with SMA type IIIa, and they were 97%, 89%, and 67%, respectively, in patients with SMA type IIIb.

Conclusions
The definition of long-term characteristics of SMA is helpful in providing medical care to families with members who have SMA and also in providing important information for future genotype-phenotype studies and therapeutic trials of patients with SMA. Our data indicate that the widely used classification schemes did not consider the broad spectrum of SMA so a practical modification was suggested.

Author Affiliations
From the Institute for Human Genetics, University of Bonn (Germany).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Delivery of a read-through inducing compound, TC007, lessens the severity of a spinal muscular atrophy animal model
Mattis et al.
Hum Mol Genet 2009;18:3906-3913.
ABSTRACT | FULL TEXT  

LBH589 induces up to 10-fold SMN protein levels by several independent mechanisms and is effective even in cells from SMA patients non-responsive to valproate
Garbes et al.
Hum Mol Genet 2009;18:3645-3658.
ABSTRACT | FULL TEXT  

Role of Survival Motor Neuron Complex Components in Small Nuclear Ribonucleoprotein Assembly
Ogawa et al.
J. Biol. Chem. 2009;284:14609-14617.
ABSTRACT | FULL TEXT  

Survival motor neuron gene 2 silencing by DNA methylation correlates with spinal muscular atrophy disease severity and can be bypassed by histone deacetylase inhibition
Hauke et al.
Hum Mol Genet 2009;18:304-317.
ABSTRACT | FULL TEXT  

Natural history of SMA IIIb: Muscle strength decreases in a predictable sequence and magnitude
Deymeer et al.
Neurology 2008;71:644-649.
ABSTRACT | FULL TEXT  

Plastin 3 Is a Protective Modifier of Autosomal Recessive Spinal Muscular Atrophy
Oprea et al.
Science 2008;320:524-527.
ABSTRACT | FULL TEXT  

The changing natural history of spinal muscular atrophy type 1
Oskoui et al.
Neurology 2007;69:1931-1936.
ABSTRACT | FULL TEXT  

Gemin2 Plays an Important Role in Stabilizing the Survival of Motor Neuron Complex
Ogawa et al.
J. Biol. Chem. 2007;282:11122-11134.
ABSTRACT | FULL TEXT  

Randomized, double-blind, placebo-controlled trial of phenylbutyrate in spinal muscular atrophy
Mercuri et al.
Neurology 2007;68:51-55.
ABSTRACT | FULL TEXT  

Determination of SMN1/SMN2 Gene Dosage by a Quantitative Genotyping Platform Combining Capillary Electrophoresis and MALDI-TOF Mass Spectrometry
Kao et al.
Clin. Chem. 2006;52:361-369.
ABSTRACT | FULL TEXT  

Spinal Muscular Atrophy: Survival Pattern and Functional Status
Chung et al.
Pediatrics 2004;114:e548-e553.
ABSTRACT | FULL TEXT  

Spinal muscular atrophy-type I
Hardart and Truog
Arch. Dis. Child. 2003;88:848-850.
FULL TEXT  

Reliability of 4 Outcome Measures in Pediatric Spinal Muscular Atrophy
Iannaccone and Hynan
Arch Neurol 2003;60:1130-1136.
ABSTRACT | FULL TEXT  

Classical infantile spinal muscular atrophy with SMN deficiency causes sensory neuronopathy
Rudnik-Schoneborn et al.
Neurology 2003;60:983-987.
ABSTRACT | FULL TEXT  

Pilot trial of albuterol in spinal muscular atrophy
Kinali et al.
Neurology 2002;59:609-610.
ABSTRACT | FULL TEXT  

Respiratory Support in Spinal Muscular Atrophy Type I: A Survey of Physician Practices and Attitudes
Hardart et al.
Pediatrics 2002;110:e24-24.
ABSTRACT | FULL TEXT  

Spinal Muscular Atrophy Type 1: A Noninvasive Respiratory Management Approach
Bach et al.
Chest 2000;117:1100-1105.
ABSTRACT | FULL TEXT  

Inactivation of the survival motor neuron gene, a candidate gene for human spinal muscular atrophy, leads to massive cell death in early mouse embryos
Schrank et al.
Proc. Natl. Acad. Sci. USA 1997;94:9920-9925.
ABSTRACT | FULL TEXT